Ipsen keeps on making case for Botox rival Dysport

15 January 2021

Sharing results at the TOXINS 2021 conference, organized by the International Neurotoxin Association, French drugmaker Ipsen (Euronext: IPN) has announced new Phase III analyses for Dysport (abobotulinumtoxinA).

The results highlight the length of the duration of response for Dysport, an injectable form of a botulinum neurotoxin, in five therapeutic indications.

The product, which is approved in more than 90 countries, works by blocking the effective transmission of nerve impulses and thereby reducing muscular contractions.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK